References
1. EA E, P T, J B, et al. New response evaluation criteria in solid
tumours: revised RECIST guideline (version 1.1). Eur J Cancer .
2009;45(2):228-247. doi:10.1016/J.EJCA.2008.10.026
2. Murray MJ, Bailey S, Heinemann K, et al. Treatment and outcomes of UK
and German patients with relapsed intracranial germ cell tumors
following uniform first-line therapy. Int J Cancer .
2017;141(3):621-635. doi:10.1002/ijc.30755
3. Modak S, Gardner S, Dunkel IJ, et al. Thiotepa-based high-dose
chemotherapy with autologous stem-cell rescue in patients with recurrent
or progressive CNS germ cell tumors. J Clin Oncol .
2004;22(10):1934-1943. doi:10.1200/JCO.2004.11.053
4. Bouffet E. The role of myeloablative chemotherapy with autologous
hematopoietic cell rescue in central nervous system germ cell tumors.Pediatr Blood Cancer . 2010;54(4):644-646. doi:10.1002/pbc.22376
5. Callec L, Lardy-Cleaud A, Guerrini-Rousseau L, et al. Relapsing
intracranial germ cell tumours warrant retreatment. Eur J Cancer .
2020;136:186-194. doi:10.1016/j.ejca.2020.06.012
6. Murray MJ, Bailey S, Heinemann K, et al. Treatment and outcomes of UK
and German patients with relapsed intracranial germ cell tumors
following uniform first-line therapy. Int J Cancer .
2017;141(3):621-635. doi:10.1002/ijc.30755
7. Murray MJ, Bartels U, Nishikawa R, Fangusaro J, Matsutani M,
Nicholson JC. Consensus on the management of intracranial germ-cell
tumours. Lancet Oncol . 2015;16(9):e470-e477.
doi:10.1016/S1470-2045(15)00244-2
8. Calaminus G, Frappaz D, Kortmann RD, et al. Outcome of patients with
intracranial non-germinomatous germ cell tumors—lessons from the
SIOP-CNS-GCT-96 trial. Neuro Oncol . 2017;19(12):1661-1672.
doi:10.1093/neuonc/nox122
Supplemental figure S1: Series of head (axial T2-weighted turbo
spin echo sequences) and spine (sagittal post-gadolinium T1-weighted
turbo echo sequences) MR examinations. A 12 year-old male presented with
a lobulated neoplastic pineal mass (A1; arrow), biopsy-proven to be a
yolk sac tumour, approximately measuring 4 x 2.5 x 4 cm (ap tr cc/ob),
markedly vascularised but non-high-cellular, and containing a couple of
subcentimetric central cystic foci. This lesion compressed and distorted
the third ventricle causing moderate obstructive hydrocephalus and
exerted mass effect also onto the right dorsal medial thalamic nuclei
and onto the ipsilateral dorsal midbrain along its aqueduct. No
intracranial or spinal metastases at baseline (A2). Favourable response
to chemotherapy and radical VMAT therapy was achieved 7 months after
diagnosis with a minimal cystic residuum (B1; arrow) which has remained
stable over time (C1, D1; arrow). However, 23 months after end of
treatment a millimetric faintly enhancing leptomeningeal deposit
overlying the cord at the level of T10-11 (B2; circle) developed. This
resolved (C2) the following year, after completion of further
chemotherapy, autologous stem cell transplant, and craniospinal
irradiation and has not reoccurred (D2) to date, 5 years off treatment.